KebedeHBegnaMD

PubMed

• A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
  Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, Catherine S Diefenbach, Daniel N Egan
  Blood Advances. 2025-02-25
• 2 citations
  Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
  Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
  American Journal of Hematology. 2025-02-01
• TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.
  Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, Saubia Fathima, Kebede H Begna
  American Journal of Hematology. 2025-01-28

Journal Articles

• Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring Sideroblasts  
  Abhishek A Mangaonkar, Kebede H Begna, Leukemia Research

Abstracts/Posters

• Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
  Kebede H. Begna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504...
  Kebede H. Begna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018